Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. August 2017 07:30 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
08. August 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Reports Second Quarter 2017 Financial Results

NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
23. Juni 2017 09:36 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
06. Juni 2017 07:30 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference

NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
18. Mai 2017 07:30 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting

NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
10. Mai 2017 17:12 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Reports First Quarter 2017 Financial Results

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
01. Mai 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference

NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
23. März 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN

NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
16. März 2017 19:25 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results

NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
10. März 2017 07:00 ET | Quelle: Stemline Therapeutics

Stemline Therapeutics to Present at the 29th Annual ROTH Conference

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...

Vorherige Seite

Nächste Seite